Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.75 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080928 | 1.00 | FDPS (0.75) | FDPSANPEPERAP2KDM4EMMP2 | |
| SCHEMBL203348 | 1.00 | FDPS (0.75) | FDPSANPEPERAP2KDM4EMMP2 | |
| SCHEMBL9356971 | 0.89 | FDPS (0.62) | FDPS | |
| SCHEMBL2203676 | 0.88 | FDPS (0.85) | FDPSANPEPERAP2MMP2 | |
| SCHEMBL26029597 | 0.87 | FDPS (0.60) | FDPS | |
| SCHEMBL2472093 | 0.86 | FDPS (1.00) | FDPSANPEPERAP2MMP2 | |
| N-(Hexamethyleneimino)Methylenebisphosphonic Acid SCHEMBL12309768 | 0.86 | FDPS (1.00) | FDPSANPEPERAP2MMP2 | |
| SCHEMBL9565325 | 0.82 | FDPS (0.60) | FDPSANPEPERAP2 | |
| Thiomorpholinomethylenediphosphonic Acid SCHEMBL1471965 | 0.82 | FDPS (1.00) | FDPS | |
| Morpholinomethylenediphosphonic Acid SCHEMBL3058156 | 0.82 | FDPS (0.60) | FDPSANPEPKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4694940-A1 | STEAP2-TARGETED COMPOUNDS AND USE THEREOF | Astrazeneca AB (SE) | 2026-02-18 | — | — | EP | claimed |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | C-BIOMEX CO., LTD. (KR) | 2025-12-02 | — | — | US | claimed |
| US-20250270257-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | C-BIOMEX CO., LTD. (KR) | 2025-08-28 | — | — | US | claimed |
| US-20250121104-A1 | EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF | ASTRAZENECA UK LIMITED (GB) | 2025-04-17 | — | — | US | claimed |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2025-02-27 | — | — | US | claimed |
| WO-2024216389-A9 | CLAUDIN 18.2-TARGETED COMPOUNDS AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2025-01-23 | — | — | WO | claimed |
| US-20250001019-A1 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. (CA) | 2025-01-02 | — | — | US | claimed |
| US-20240408249-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-12-12 | — | — | US | claimed |
| EP-4452954-A2 | EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2024-10-30 | — | — | EP | claimed |
| US-5318772-A | Polyaminemethylenephosphonic acids of diethylenediamine, norbornanediamne, 1,4,7,10-tetraazacyclododecane, 3,6,9,15-tetraazabicyclo(9.3.1)pentadecatriene or 1,4,7-triazanonane and a suitable vehicle | THE DOW CHEMICAL COMPANY (US) | 1994-06-07 | — | — | US | claimed |
| US-5300281-A | Radiolabeled compositions containing a calcific matrix and their use for treatment of arthritis | THE DOW CHEMICAL COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| WO-1993011741-A1 | ORAL COMPOSITIONS FOR INHIBITING PLAQUE AND CALCULUS FORMATION | THE DOW CHEMICAL COMPANY (US) | 1993-06-24 | — | — | WO | claimed |
| EP-0468634-A1 | The use of macrocyclic aminophosphonic acid complexes as imaging agents | THE DOW CHEMICAL COMPANY (US) | 1992-01-29 | — | — | EP | claimed |
| US-5064633-A | Macrocyclic aminophosphonic acid complexes, their formulations and use | THE DOW CHEMICAL COMPANY (US) | 1991-11-12 | — | — | US | claimed |
| EP-0408701-A4 | MACROCYCLIC AMINOPHOSPHONIC ACID COMPLEXES, THEIR PREPARATION, FORMULATIONS AND USE | — | 1991-07-31 | — | — | EP | claimed |
| EP-0411941-A2 | Process for purifying aminomethylenephosphonic acids | THE DOW CHEMICAL COMPANY (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0408701-A1 | MACROCYCLIC AMINOPHOSPHONIC ACID COMPLEXES, THEIR PREPARATION, FORMULATIONS AND USE. | DOW CHEMICAL CO (US) | 1991-01-23 | — | — | EP | claimed |
| WO-1990006776-A1 | MACROCYCLIC AMINOPHOSPHONIC ACID COMPLEXES, THEIR PREPARATION, FORMULATIONS AND USE | THE DOW CHEMICAL COMPANY (US) | 1990-06-28 | — | — | WO | claimed |
| US-4937333-A | Method for purifying aminomethylenephosphonic acids for pharmaceutical use | THE DOW CHEMICAL COMPANY (US) | 1990-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270257-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | CA9, CA4, CA12 | FDPS 2049/4885ANPEP 14/4885ERAP2 216/4885 |
| US-20240408249-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | EGFR, ERBB3, ERBB2 | FDPS 4758/4885ANPEP 275/4885ERAP2 1317/4885 |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | CA9, CA4, CA12 | FDPS 2049/4885ANPEP 14/4885ERAP2 216/4885 |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | FDPS 2929/4885ANPEP 104/4885ERAP2 733/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | FDPS 1487/4885ANPEP 159/4885ERAP2 677/4885 |
| US-20250001019-A1 | METHODS OF TREATING CANCER | IGF1R, IGFBP1, IGFBP2 | FDPS 4806/4885ANPEP 728/4885ERAP2 2359/4885 |
| US-20250121104-A1 | EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB4 | FDPS 4681/4885ANPEP 213/4885ERAP2 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.